Showing results (151-160 of 741) with videos related to
Sort By:
Pageof 75
Blood Cancer Journal|January 16, 2024
Mode of progression in smoldering multiple myeloma: a study of 406 patientsNadine H Abdallah, Arjun Lakshman, Shaji K Kumar, et al.American Journal of Hematology|July 7, 2015
Predictors of early response to initial therapy in patients with newly diagnosed symptomatic multiple myelomaMoritz Binder, S Vincent Rajkumar, Morie A Gertz, et al.Blood Cancer Journal|April 15, 2020
A validated composite organ and hematologic response model for early assessment of treatment outcomes in light chain amyloidosisSurbhi Sidana, Paolo Milani, Moritz Binder, et al.Blood|September 30, 2006
The activity of lenalidomide with or without dexamethasone in patients with primary systemic amyloidosisAngela Dispenzieri, Martha Q Lacy, Steven R Zeldenrust, et al.NPJ Precision Oncology|April 14, 2026
Proteomic profiling revealed unique disease biology associated with 1q abnormalities in multiple myelomaKiran K Mangalaparthi, Joel-Sean Hsu, J Erin Wiedmeier-Nutor, et al.American Journal of Hematology|August 13, 2004
Cell proliferation of myeloma plasma cells: comparison of the blood and marrow compartmentsShaji Kumar, S Vincent Rajkumar, Philip R Greipp, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 22, 2005
Proteasome inhibition as a novel therapeutic target in human cancerS Vincent Rajkumar, Paul G Richardson, Teru Hideshima, et al.British Journal of Haematology|July 9, 2003
Bone marrow angiogenesis and circulating plasma cells in multiple myelomaShaji Kumar, Thomas E Witzig, Philip R Greipp, et al.American Journal of Hematology|May 1, 2020
Role of imaging in multiple myelomaFrancis I Baffour, Katrina N Glazebrook, Shaji K Kumar, et al.American Journal of Hematology|August 12, 2014
Immunoglobulin light chain amyloidosis is diagnosed late in patients with preexisting plasma cell dyscrasiasTaxiarchis V Kourelis, Shaji K Kumar, Ronald S Go, et al.Pageof 75